Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-042466
Filing Date
2025-02-28
Accepted
2025-02-28 16:05:47
Documents
16
Effectiveness Date
2025-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 d830727ds8.htm S-8 32954
2 EX-5.1 d830727dex51.htm EX-5.1 6226
3 EX-23.1 d830727dex231.htm EX-23.1 1520
4 EX-FILING FEES d830727dexfilingfees.htm   iXBRL EX-FILING FEES 33812
5 GRAPHIC g830727g0228063428399.jpg GRAPHIC 2639
  Complete submission text file 0001193125-25-042466.txt   233039

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT d830727dexfilingfees_htm.xml XML 15348
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285416 | Film No.: 25690023
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)